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Edited by Judit Ova´diAbstract b-Secretase is the rate limiting enzymatic activity in
the production of amyloid-b peptide, the primary component of
senile plaque pathology in Alzheimer’s disease (AD). This study
performed the ﬁrst comparative analysis of b-secretase enzyme
kinetics in AD and control brain tissue. Results found Vmax val-
ues for b-secretase to be signiﬁcantly increased, and Km values
unchanged in AD temporal cortex compared to matched control
temporal cortex. The increased Vmax in AD cases, did not corre-
late with levels of BACE1, and decreased BACE1 and BACE2
levels correlated with the severity of neuroﬁbrillary pathology
(I–VI), and synaptic loss in AD. These results indicate that in-
creased Vmax for b-secretase is a feature of AD pathogenesis
and this increase does not correlate directly with levels of
BACE1, the principal b-secretase in brain.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The b-secretase enzyme is the subject of signiﬁcant attention
in the understanding and treatment of Alzheimer’s disease
(AD), as it is the rate limiting activity in the production of
the 4 kDa amyloid-b (Ab) peptide, the primary component
of senile plaque pathology in AD [1,2]. b-Secretase cleaves
the amyloid precursor protein (APP) at the N terminal Asp-
1 position of Ab, to generate a soluble ectodomain (sAPPb),
and a membrane-bound APP C-terminal fragment of 99 amino
acids. The latter can be cleaved subsequently by c-secretase to
produce the 39–43 amino acid peptide, Ab [2]. Two highly
homologous type 1 single transmembrane aspartyl proteases
BACE1 (b-site APP cleaving enzyme, also known as, Asp2,Abbreviations: Ab, amyloid b-peptide; AD, Alzheimer’s disease; APP,
amyloid precursor protein; BACE, b-site APP-cleaving enzyme; DNP,
2,4-dinitrophenyl; EDTA, ethylene-diamine-tetra-acetic acid; HEK-
293, human embryonic kidney 293; Km, Michaelis constant; MCA,
7-methoxycoumarin-4-acetic acid; NFT, neuroﬁbrillary tangles;
PMSF, phenylmethylsulphonyl ﬂuoride; SDS–PAGE, sodium dodecyl
sulphate–polyacrylamide gel electrophoresis; Vmax, maximal velocity;
TBS-T, Tris-buﬀered saline, Tween
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identiﬁed to have b-secretase activity [3–9], and a number of
studies provide evidence indicating that BACE1 is the major
b-secretase responsible for Ab generation in the brain. In par-
ticular, mice with targeted homozygous deletion of the BACE1
gene almost completely abolish the production of Ab peptides
in the brain [10–12]. Although BACE2 can cleave at the b-
secretase site of APP [4,9], its mRNA tissue distribution [13]
and its preference for cleavage within the Ab region at Phe
19 and Phe 20, is not consistent with requirements for b-secre-
tase activity in the brain [9,14–16].
Previous studies examining b-secretase activity in post-mor-
tem human brain, and in AD, have used a single concentration
of substrate, and show variable, but generally increased activ-
ity of the enzyme in AD compared to non-AD control brain
[17–21]. However, analysis of b-secretase enzyme kinetics is
lacking. It is thus unknown whether the reported increased
activity in AD brain is reﬂected by changes in Michaelis con-
stant (Km) and maximal velocity (Vmax) values for the protease,
which is important for understanding the dynamics of b-secre-
tase activity in AD, and in eﬀective inhibitor design. Moreover,
the relationship between the kinetics of b-secretase activity, the
severity of AD pathology, and BACE1 protein levels are un-
known. Comparative analysis of BACE1 levels in various re-
gions of AD and control brain have detected signiﬁcant
variation, when comparing control and disease groups, with
diﬀering molecular weights for BACE1, evident between stud-
ies. These are most likely to reﬂect BACE1 maturation
through the secretory pathway from prozymogen (45–
50 kDa) to fully mature N-glycosylated forms [22–24]. Thus,
BACE1 has been detected at 70–72 kDa, with a 2.7-fold in-
crease in AD frontal cortex [25], at 70 kDa, increased by
28% and 32% in AD frontal cortex and hippocampus, respec-
tively [17,19]; bands of 70 and 50 kDa, showing increases of
14% and an insigniﬁcant trend towards an increase of 15% in
the AD frontal and temporal cortex, respectively [18], and a
55 kDa band with unchanged levels in AD parietal cortex,
compared to control cases [26].
BACE2 mRNA is expressed at low levels in the brain, when
compared to BACE1 mRNA [4,13], however, BACE2 protein
has been detected in both control and AD pyramidal neurons
[4], and at various molecular weights in human [27,28] and rat
[29] brain. No deﬁnitive investigation has comparatively quan-
tiﬁed BACE2 protein levels in AD and non-AD control brain.
This requires investigation, as it is possible that BACE2 levels
may be altered in AD. BACE2 activity is predicted for the
most part to preclude Ab generation, and may act antagonis-
tically to BACE1 [30], thus, decreased BACE2 levels may con-ation of European Biochemical Societies.
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AD. Large increases in BACE2 levels in AD brain may con-
tribute to Ab accumulation, as the BACE2 gene resides on
the Down’s syndrome obligate region of chromosome 21,
and increased levels of the protein have been detected in Tri-
somy 21 brain which accumulate Ab [27,28].
Together, the evidence above led us to examine the kinetics
of b-secretase enzyme activity, as well as BACE1 and BACE2
protein levels in AD and matched control mid-temporal cor-
tex, in which the brains were staged for disease severity, as
measured by Braak staging for neuroﬁbrillary changes [31].
We report a signiﬁcant increase in the Vmax for b-secretase
activity in AD cases compared to control cases which did
not correlate with the severity of AD, or with levels of BACE1,
the principal b-secretase in the brain. Together results indicate
a complex control of b-secretase enzyme kinetics and its major
associated enzyme BACE1 in AD.2. Materials and methods
2.1. Human brain tissue
Human brain tissue was provided by the Netherlands Brain Bank
(see Table 1 for case details). Ethical approval and written informed
consent from the donors or the next of kin was obtained in all cases.
AD cases (n = 9) were diagnosed according to the NINCDS-ADRDA
criteria, and severity of dementia rated by the Global Deterioration
Scale. Non-disease controls (n = 7) had no history or symptoms of neu-
rological or psychiatric disorders. All cases were neuropathologically
conﬁrmed, using conventional histopathological techniques, and diag-
nosis performed using the CERAD criteria. Neuropathological staging
of neuroﬁbrillary changes (I–VI) and amyloid plaques (O–C) was per-
formed according to Braak and Braak [31]. The nine AD and seven
non-demented control cases were matched for post-mortem delay (con-
trol ± S.E.M., 6.0 ± 0.4 h; AD ± S.E.M., 5.7 ± 0.6 h; P = 0.66); age
(control ± S.E.M., 72 ± 4.6 years; AD ± S.E.M., 77.9 ± 3.6 years;
P = 0.29); brain-weight (control ± S.E.M., 1230 ± 60 g; AD ± S.E.M.,
1112 ± 54 g; P = 0.14) as well as tissue pH (control ± S.E.M.,
6.9 ± 0.2; AD ± S.E.M., 6.7 ± 0.1; P = 0.41), the latter, as an index
of agonal status and tissue quality. P-values indicate no signiﬁcant dif-
ference between post-mortem delay, age, brain weight or tissue pH
when comparing AD and control cases.
2.2. Preparation of tissue fractions
Human brain tissue fractions from the mid-temporal cortex were
prepared as previously described [32], using conditions that were com-
patible with measuring both b-secretase activity, and detection of
BACE1/BACE2 by western immunoblot analysis. Brieﬂy, frozen brain
tissue was thawed rapidly at 37 C in homogenisation buﬀer [20 mM
PIPES–KOH (pH 7.4), 0.32 M sucrose, 1 lg/ml leupeptin, 1 lg/ml
aprotinin, 1 lg/ml pepstatin and 0.5 mM phenylmethylsulphonyl ﬂuo-
ride (PMSF)]. Tissue was homogenised using 10 volumes (w/v) of
ice-cold homogenisation buﬀer, and centrifuged in a Beckman ultra-
centrifuge at 100000 · gmax for 60 min at 4 C (Beckman Type 42.1
rotor). Particulate fractions (100000 · gmax pellet), enriched in mem-
branes, were separated from cytosolic fractions (100000 · gmax super-
natant) and suspended in 5 volumes (w/v) of homogenisation buﬀer,
prior to storage of fractions at 70 C. Rat brain cortical tissue from
female Sprague-Dawley rats (age 12–16 weeks) was homogenised in
ice-cold homogenisation buﬀer as above, aliquoted and stored at
70 C. Protein concentrations were determined using a modiﬁed
Lowry procedure with bovine serum albumen as standard [33]. Brain
homogenates from BACE1 knock-out (KO) and wild-type litter mate
controls were prepared as previously described [10].
2.3. b-Secretase enzyme activity assay
b-Secretase activity and kinetic analysis was measured using a
quenched ﬂuorescence assay, with a synthetic peptide substrate based
on the b-secretase cleavage site of wild-type APP (MCA)Glu-Val-
Lys-Met-ﬂ-Asp-Ala-Glu-Phe-Lys(DNP) (Calbiochem, UK), and amodiﬁcation of a previously described assay system [34], employing
the principal of ﬂuorescence resonance energy transfer (FRET). The
substrate peptide ﬂanks the b-secretase cleavage site, separating a ﬂuo-
rophore donor (MCA), from an acceptor quenching group (DNP).
Hydrolysis of the peptide separates the ﬂuorophore from the quench-
ing group, resulting in an increase in ﬂuorescence proportional to the
amount of peptide hydrolysed. Enzyme reactions were carried out at
37 C, in brown microfuge tubes (Sarstedt, DE), in a ﬁnal volume of
100 ll of reaction buﬀer (50 mM sodium acetate, pH 4.5), containing
varying concentrations of substrate, and 20 ll of diluted brain fraction.
Unless otherwise stated, 1 lg of protein from control and AD partic-
ulate fractions was used in all reactions, with an incubation time of
1 h, after linearity between protein concentration (0.3–12 lg), time
(examined up to 120 min, data not shown) and ﬂuorescence intensity
was determined in control human brain fractions (n = 3). For inhibitor
studies 10 ll of b-secretase inhibitor P10–P40 StatVal (H-Lys-Thr-Glu-
Glu-Ile-Ser-Glu-Val-Asn-Stat-Val-Ala-Glu-Phe-OH [Stat = (3S,4S)-
Statine]) (Calbiochem), at concentrations of 0.1 nM to 6.5 lM, was
incubated with 20 ll of protein for 30 min at 37 C, prior to addition
of reaction buﬀer with 15 lM substrate, and incubation at 37 C for
1 h. For kinetic analysis 1 lg of protein was incubated with increasing
concentrations of substrate (1–50 lM) for 1 h at 37 C with reaction
buﬀer containing a maximum of 1.4% dimethyl sulfoxide. All reactions
were stopped by boiling samples at 100 C for 10 min, followed by
centrifugation at 9500 · gmax for 10 min, 80 ll of reaction sample
was removed and diluted in 400 ll of deionised water and ﬂourescent
7-methoxycoumarin-4-acetic acid (MCA) cleavage product measured.
An excitation wavelength of 320 nm and an emission wavelength
of 393 nm were used to measure the hydrolysis of substrate on a
Perkin-Elmer LS50 B ﬂuorescence spectroﬂuorometer, and readings
compared against a standard curve of MCA (Sigma-Aldrich, UK)
dissolved in 50 mM sodium acetate pH 4.5.2.4. Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were grown to conﬂuence
in Dulbecco’s modiﬁed Eagle’s medium containing 10% fetal bovine
serum and 1% L-glutamine. All reagents were obtained from Sigma-Al-
drich, unless otherwise stated. Cells were maintained in a humidiﬁed
37 C incubator with 5% CO2. Cells at 70% conﬂuency were transfec-
ted, using the calcium phosphate DNA precipitation technique.
Brieﬂy, 4 lg of pcDNA3.1 vector encoding C-terminal Myc-His tagged
BACE1, C-terminal Myc-His BACE2 (generous gifts from Dr. J.V.
McCarthy), or empty vector were diluted in 62 ll of 2 M CaCl2,
brought to 500 ll with deionised water and mixed, before drop wise
addition to 500 ll of 2· Hank’s balanced saline solution solution,
and addition of the mixture to cells for 8 h. Media was refreshed,
and cells left to grow for 16 h before harvesting. Cells were lysed in
0.1% NP-40 (v/v), 150 mM NaCl, 50 mM N-[2-hydroxyethyl]pipera-
zine-N 0-[2-ethanesulfonic acid], 1 mM EDTA, 1 mM Na3VO4, 1 lg/
ml leupeptin, 1 lg/ml aprotinin, 1 lg/ml pepstatin and 0.5 mM PMSF,
for 20 min on ice and centrifuged at 20000 · gmax for 10 min at 4 C.
Supernatants were retained and protein concentration determined
using Bio-Rad reagent (Bio-Rad, UK) with bovine serum albumen
as standard. For deglycosylation experiments, cell lysates (100 lg pro-
tein) were denatured by boiling at 100 C for 10 min in 0.1% SDS,
0.5 mM 2-mercaptoethanol and 50 mM sodium phosphate buﬀer (ﬁnal
volume of 100 ll). NP-40 was added to a ﬁnal concentration of 0.75%
(v/v) before treatment with or without 1 U of PNGase F (Sigma-Al-
drich) for 17 h at 37 C. Enzymatic digestion of samples was examined
by immunoblotting.2.5. Sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) and immunoblotting
20 lg of protein was resolved on 10% SDS–PAGE for all Western
blot analyses. Proteins were transferred electrophoretically to nitrocel-
lulose membranes (0.45 lM, Schleicher and Schuell, DE) using a wet
transfer blotting apparatus (75 V, 75 min). The transfer buﬀer for
immunoblots consisted of 48 mM Tris, 39 mM glycine and 20% etha-
nol. Nitrocellulose membranes were blocked for 1 h in 150 mM NaCl,
10 mM Tris–HCl, pH 8.0, 0.1% Tween 20 (TBS-T, Tris-buﬀered saline,
Tween) and 5% w/v non-fat dry milk. Immunoblots were incubated
overnight at 4 C with the various primary antibody solutions diluted
in TBS-T with 5% non-fat dry milk. Antisera dilutions and sources
were as follows: BACE1 485-501 (1:2000 dilution, Calbiochem);
Table 1
Neuropathological details, Vmax and Km values for control and AD cases
NFT stage Senile plaques APOE genotype Gender Age (years) Tissue pH PMD (h) Brain weight (g) Vmax (nM/min) Km (lM) BACE1 (75 kDa)
Control cases
C1 O C E3/E3 f 78 7.00 6.35 1084 3.75 2.61 424
C2 O – E4/E3 m 62 7.33 6.35 1352 6.50 8.20 515
C3 O O E3/E3 f 54 6.45 8.00 1257 3.70 5.55 289
C4 I O E3/E3 f 68 6.89 5.45 1194 2.70 4.01 510
C5 I O E3/E3 f 83 7.30 5.15 1000 1.10 10.05 541
C6 II O E3/E3 m 74 7.02 5.53 1328 2.33 19.32 508
C7 II A E3/E2 m 85 6.23 5.13 1394 5.36 4.62 477
Average 72 ± 4.6 6.9 ± 0.2 6.0 ± 0.4 1230 ± 60 3.6 ± 0.8 7.8 ± 2.3 466 ± 35
AD cases
A1 IV C E4/E3 m 78 6.64 4.30 1315 4.25 4.54 357
A2 IV C E4/E3 f 90 6.50 6.15 1117 11.51 11.41 497
A3 IV C E3/E3 f 88 6.65 5.35 1112 2.72 4.58 392
A4 V C E3/E3 f 74 7.36 6.05 934 5.18 5.58 152
A5 V C E3/E3 m 61 6.92 4.15 1260 1.15 11.79 253
A6 VI C E4/E3 m 84 6.67 4.35 1084 7.25 6.70 371
A7 VI – E4/E3 f 87 6.84 6.15 956 7.34 8.39 369
A8 VI C E3/E3 f 72 6.40 9.50 935 7.79 11.80 60
A9 VI C E4/E3 m 67 6.70 5.05 1296 / / 326
Average 77.9 ± 3.6 6.7 ± 0.1 5.7 ± 0.6 1112 ± 54 5.9 ± 1.2 8.1 ± 1.1 308 ± 47
P value 0.29 0.41 0.66 0.14
PMD, post-mortem delay; f, female; m, male; P value, probability value obtained through Student’s t test comparing control and AD variables.
6
5
5
2
J
.H
.
S
to
ck
ley
et
a
l.
/
F
E
B
S
L
etters
5
8
0
(
2
0
0
6
)
6
5
5
0
–
6
5
6
0
A0.3
0.6
0.9
1.2
1.5
[M
C
A]
μM
J.H. Stockley et al. / FEBS Letters 580 (2006) 6550–6560 6553BACE1 485–501 (1:1000, Abcam, UK); BACE2 44–59 (1:4000 dilu-
tion, Calbiochem); BACE2 44–59 (1:2000 dilution, Abcam); b-Actin
(1:10000 dilution, Sigma-Aldrich); ﬂotillin-1 (1:1000 dilution, BD Bio-
sciences, USA); synaptophysin (1:50000 Sigma-Aldrich); c-Myc 9e10
(1:1000 dilution, Abcam) and APP 22C11 (1:1000 dilution, Chemicon,
USA). Nitrocellulose membranes were washed three times in TBS-T
for a total of 30 min, followed by incubation with a 1:1000 dilution
of horseradish peroxidase-linked anti-rabbit or anti-mouse (Dako,
UK) secondary antibody in TBS-T for 1 h at room temperature. Blots
were washed as described above, and immunoreactive proteins were
detected with enhanced chemiluminescence (GE Healthcare, UK).0 2 4 6 8 10 12
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μM2.6. Data analysis
Values presented represent means ± S.E.M. Kinetic isotherms (Vmax
and Km values) for b-secretase activity were determined by means of
non-linear least squares ﬁtting to the Michaelis–Menten equation using
GraphPad Prism software (v 4.0 for Windows, ISI Software San
Diego, CA, USA). IC50 values were determined using GraphPad Prism
software. Immunoreactivity from immunoblots was quantiﬁed by den-
sitometry (GeneGenius Gel Documentation and Analysis System/Syn-
gene). Results were obtained and analysed as absolute values (total
integrated volume). The signiﬁcance of diﬀerence between control
and AD groups was analysed by two-tailed Student’s t-test, with
P < 0.05 considered signiﬁcant. Correlation between various parame-
ters was made using regression analyses (Pearson correlation coeﬃ-
cient) and GraphPad Prism software. Signiﬁcance was determined
using the table of signiﬁcant correlation coeﬃcients, based on r2-val-
ues.C
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C AD
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Fig. 1. (A) Relationship between increasing concentration of human
control brain protein (0.3–12 lg), and the hydrolysis of ﬂourogenic
APP peptide substrate, measured by ﬂuorescence intensity of the
cleavage product compared to a standard curve of known concentra-
tions of MCA. Values are mean of three separate determinations, error
bars are contained within the data points. (B) Dose dependent
inhibition of the hydrolysis of ﬂuorogenic APP peptide substrate in
control human brain fractions by the b-secretase inhibitor P10–P40
StatVal. The IC50 for P10–P4
0 StatVal inhibition was 41 nM. Data
represent means ± S.E.M. for three separate experiments. (C) b-
Secretase enzyme activity at a single substrate concentration (15 lM)
in control and AD cases, in the absence (I) and presence (I+) of the
b-secretase inhibitor P10–P40 StatVal (2.1 lM). Values represent
means ± S.E.M. for n = 7 control cases, and n = 9 AD cases. In all
experiments particulate fractions were incubated with ﬂuorogenic APP
peptide substrate at 37 C for 1 h.3. Results
To examine b-secretase activity in human brain, a commer-
cially available ﬂuorogenic substrate mimicking wild-type APP
(MCA-EVKMDAEFK(DNP)-NH2) was employed, and b-
secretase activity was determined from the ﬂuorescent signal
of the MCA cleaved product generated as described in the
methods section. b-secretase enzyme activity in human brain
particulate fractions demonstrated high sensitivity, and linear-
ity with time (times up to 120 min examined, data not shown)
and with sample protein concentration in the range 0.3–12 lg
(Fig. 1A). Hence, 1 lg of protein was selected for all future
experiments. Speciﬁcity of the activity assay was conﬁrmed
using the speciﬁc peptide inhibitor of b-secretase activity
P10–P4 0 StatVal (KTEETSEVN(stat)VAEF) originally de-
scribed by Sinha et al. [5]. This exhibited a dose-dependent
inhibition of b-secretase activity (15 lM substrate), with an
IC50 of 41 nM (Fig. 1B). Single point analysis (15 lM sub-
strate) of b-secretase activity in control (n = 7) and AD
(n = 9) cases was variable between samples, and the increased
activity in AD detected compared to control did not attain sig-
niﬁcance. Activity was completely abolished in all samples
using saturating dose of inhibitor (2.1 lM) (Fig. 1C).
To compare the kinetics of the b-secretase enzymatic activity
in AD and non-AD control cases, we examined the activity of
b-secretase at increasing substrate concentration (1–50 lM), in
AD (n = 9) and control (n = 7) temporal cortex preparations.
b-Secretase enzyme activity was saturable, and followed
Michaelis–Menten kinetics in all AD and control samples, with
the exception of one AD case (A, 9). Enzyme activity proﬁles
are shown for each individual AD (A, 1–8) and control (C, 1–
7) cases (Fig. 2A), and individual Km and Vmax values are tab-
ulated (Table 1). Vmax values showed signiﬁcant variation,
ranging from 1.10 to 11.51 nM/min; and Km values ranged
from 2.61 lM to 19.32 lM. Mean data for AD (n = 8) and
control (n = 7) groups is shown in Fig. 2B, where Vmax valueswere found to be signiﬁcantly increased (P < 0.05) in the AD
cases (5.8 ± 0.66 nM/min) compared to the controls
(3.5 ± 0.41 nM/min), and Km values were not signiﬁcantly dif-
ferent when comparing AD (7.68 ± 2.9 lM) and control
groups (5.25 ± 2.3 lM). There was no correlation between
Vmax or Km values with agonal status, post-mortem delay,
age, or gender, of the samples. In this study we selected cases
with increasing severity of pathological changes (0–VI) as mea-
sured by Braak staging [31]. These stages measure the extent of
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Fig. 2. (A (i–iv)). Comparative examination of the dependence of b-secretase activity (velocity, V nM/min) on increasing substrate concentration [S],
in the 7 individual control and 8 AD temporal cortex particulate fractions, labelled as controls, C1–C7, and AD, A1–A8. Particulate fractions (1 lg
protein) were incubated with increasing concentration of ﬂuorogenic APP peptide substrate (1–50 lM) at 37 C for 1 h. Data represent the mean of
three separate determinations for each case. The Vmax and Km values obtained for each case, by non-linear least squares ﬁtting to the Michaelis–
Menten equation, are presented in Table 1. (B) Dependence of the mean b-secretase activity on increasing substrate concentration in temporal cortex
fractions of control (j) and AD (m) cases. Data represent means ± S.E.M. for n = 7 control cases, and n = 8 AD cases. The Vmax and Km values
obtained are presented in Section 3.
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ity of AD, whereas the amyloid plaques have a more general-
ised distribution [31,35]. There was no correlation between
Vmax or Km values and the Braak staging for neuroﬁbrillary
changes (0–VI). Thus, although three of the cases with the
most severe pathology (Stage VI) had consistently high Vmax
values, two AD cases (A3, A5) had low Vmax values, and
one stage IV case had the highest Vmax value (see Table 1).
Senile plaque number and amyloid stage (O–C) as measured
by Braak and Braak did not correlate with the Km and Vmax
values of the cases.
Next, we were interested to examine the levels of BACE1
and BACE2 proteins in the same AD and control cases, and
in particular to examine the relationship between BACE1,
the principal b-secretase in the brain, and the changes of Vmax
for b-secretase activity evident in AD cases. To do this we em-
ployed antibodies directed towards epitopes speciﬁc to BACE1
and BACE2 via their C and N-termini, respectively. The
BACE1 antibodies are raised against amino acids 485–501 of
BACE1, and the BACE2 antibodies are raised against amino
acids 44–59 of BACE2. Sequences were blasted against the hu-
man database (www.ncbi.nlm.nih.gov/blast) and do not share
signiﬁcant sequence similarity with each other, or with any
other proteins in the database. Evaluation of BACE1 and
BACE2 antibody speciﬁcity was determined by immunoblot-
ting lysates of human embryonic kidney 293 (HEK293) cells
which had been transiently transfected with either C-terminal
Myc-His-tagged BACE1 (B1), C-terminal Myc-His-tagged
BACE2 (B2) or empty vector (EV). The BACE1 antibody de-
tected two bands 73 kDa and 65 kDa (Fig. 3A (i)) inBACE1 transfected cells, and did not detect or cross-react with
BACE2 protein, as no immunoreactivity was detected in the
cells overexpressing BACE2 (Fig. 3A (i)) The BACE2 antibody
detected a single immunoreactive band of 60 kDa in cells
transfected with C-terminal Myc-His-tagged BACE2
(Fig. 3A (ii)) and the BACE2 antibody did not detect or
cross-react with the BACE1 protein, as no immunoreactivity
was detected in cells overexpressing BACE1 (Fig. 3A (ii)). Ver-
iﬁcation of the presence of over-expressed BACE1 and BACE2
was conﬁrmed by reprobing the blot used in Fig. 3A (ii) with
anti c-Myc which detected BACE1 and BACE2 (Fig. 3A
(iii)) at identical molecular weights to that detected by the
BACE1 and BACE2 antibodies, respectively. Cell lysates from
BACE1 transfected cells were incubated with (+) and without
() the N-glycosidase enzyme PNGase F. A large proportion
of BACE1 is N-glycosylated as BACE1 migrates faster at
55–60 kDa in treated lysates (Fig. 3A (iv)). BACE1 antibody
speciﬁcity was further assessed by examination of immuno-
reactivity detected in BACE1 knock-out mouse brain lysates,
compared to their litter mate controls (Fig. 3A (v)). BACE1
antibody recognises a single band 73 kDa in lysates prepared
from wild-type (wt) mice (Fig. 3A (v)) but no BACE1 immuno-
reactivity was detected in lysates from BACE1 knock-out mice
(Fig. 3A (v)). Blots in Fig. 3A (v) were reprobed with anti-APP
(22C11) to conﬁrm protein loading in each lane (Fig. 3A (vi)).
BACE1 and BACE2 expression proﬁles were next examined
in human and rat brain fractions. In human brain BACE1 is
detectable as a closely spaced doublet of 73–75 kDa
(Fig. 3C upper panel), also seen as a single band on darker
exposures (Fig. 3B(i), Fig. 3C). BACE1 immunoreactivity is
Fig. 3. (A) Representative Western blots of HEK293 cell lysates (HK); HEK293 cells transfected with either: empty vector (EV); Myc-His-tagged
BACE1 (B1) or Myc-His-tagged BACE2 (B2), immunostained with the following antibodies: (i) anti-BACE1, (ii) anti-BACE2 and (iii) anti-c-Myc.
BACE1 and BACE2 immunoreactivity was only detected in cell lysates transfected with Myc-His-tagged BACE1 and Myc-His-tagged BACE2
respectively, and the same immunoreactive bands for BACE1 and BACE2 were detected with anti-c-Myc. (iv) BACE1 transfected cell lysates treated
with (+) and without () the N-glycosidase enzyme PNGase F to remove N-linked oligosaccharides. (v) Mouse brain homogenates (20 lg per lane) of
BACE1 knock-out (KO1 and KO2) and control litter mates (Wt1 and Wt2) probed with anti-BACE1, showing no BACE1 immunoreactivity in
BACE1 knock-out homogenates. Blot (v) was stripped and reprobed with anti-APP (22C11) to verify protein loading (vi). (B) Representative
immunoblots showing the relative expression of BACE1 (i) and BACE2 (ii) in particulate (lane 1) and homogenate (lane 2) fractions prepared from
control human brain (C5), and rat cortical brain lysate (lane 3). (B, (iii)) Human particulate C5 probed with another commercially available anti-
BACE2. Western blots of particulate fractions (20 lg protein per lane) prepared from AD (n = 9, A1–A9) and control (n = 7, C1–C7) cases analysed
with anti-BACE1 (C, upper and lower panel), anti-BACE2 (D), anti-ﬂotillin-1 (E) and anti-b-actin (F). Samples were loaded in alternate lanes in the
same order for (C–F), indicated on top of immunoblots and Braak staging (0–VI) for neuroﬁbrillary changes also indicated. Densitometric analysis
revealed integrated volume values for the BACE1, 75 kDa band, to be signiﬁcantly reduced (P < 0.05), BACE1 50 kDa band, to be signiﬁcantly
increased (P < 0.005), and BACE2 75 kDa band to be signiﬁcantly decreased (P < 0.05) in the AD cases compared to controls. (E) Flotillin-1 and (F)
b-Actin levels were not signiﬁcantly diﬀerent when comparing AD and control groups. All values were determined from at least three separate
immunoblot determinations.
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(100 000 · gmax, 1 h pellet) compared to homogenate fractions
prepared from control human brain, allowing detection of low-
er molecular weight forms (Fig. 3B (i), compare lanes 1 and 2).
These lower molecular weight forms include a doublet at
70 kDa and a very light band detected at 45 kDa. The spec-
iﬁcity of all BACE1 immunoreactive bands was conﬁrmed by
pre-absorption of the antibody with a blocking peptide (data
not shown). In rat brain cortical homogenates BACE1 is de-
tected as a monospeciﬁc band of 73 kDa (Fig. 3B (i), lane
3). Further experiments are necessary to verify the speciﬁcity
of the less immunoreactive lower molecular weight BACE1
bands in human brain. It is speculative to assume the lower
molecular weights of BACE1 detected here represent less gly-
cosylated forms of BACE1, as N-glycosidase treatment of
human brain preparations did not alter the molecular weight
of the bands detected, possibly owing to lack of compatibility
of the homogenisation buﬀer with the N-glycosidase. We thus
focused mainly on the major BACE1 immunoreactive band
73–75 kDa when comparing levels in AD and control brain
preparations.
BACE2 protein was detected predominantly at 73–75 kDa
in human brain particulate and homogenates fractions
(Fig. 3B (ii)) detected as a doublet with lighter exposures
(Fig. 3D), and as a monospeciﬁc band of 73 kDa in rat brain
(Fig 3B (ii)). A much less immunoreactive doublet (68–
70 kDa) was detected in human particulate fractions (Fig. 3B
(ii)). The major BACE2 immunoreactive bands thus migrate
at a higher molecular weight in the mammalian preparations
(73–75 kDa) compared to cells overexpressing BACE2
(60 kDa), and appear at a very similar molecular weights to
BACE1 immunoreactive bands in these preparations. The elec-
trophoretic mobility of the detected BACE2 bands in human
preparations, was further conﬁrmed with another BACE2 spe-
ciﬁc antibody from a diﬀerent commercial source (Fig. 3B
(iii)).
Following the above characterisation, BACE1 and BACE2
levels were analysed in the same human brain control (n = 7)
and AD (n = 9) temporal cortex particulate fractions, that
had been analysed for b-secretase kinetics. Densitometric anal-
ysis revealed that levels of the major BACE1 immunoreactive
band (73–75 kDa) doublet were variable, but decreased sig-
niﬁcantly (34%; P < 0.05) in AD cases, compared to control
cases (Fig. 3C, upper panel), a feature that was particularly
evident at later stages of the disease (Stages V and VI). Non
signiﬁcantly (P = 0.09) decreased levels of the lower less abun-
dant BACE1 70 kDa immunoreactive band (42%) were also
detected in the AD cases (Fig. 3D). A BACE1 immunoreactive
band at approximately 50 kDa, evident only at very minimal
levels in control samples was signiﬁcantly increased (82%;
P < 0.005), in AD cases compared to controls, but was only
visible on prolonged exposures of the immunoblot, (Fig. 3D,
arrowhead 50 kDa), and correlated with disease staging. When
the full series of control and AD cases were examined for
BACE2 immunoreactivity it was evident that the 73–
75 kDa band was the predominant immunoreactive band, with
very variable and extremely low levels of the 70 kDa band de-
tected (Fig. 3D). Densitometric analysis detected signiﬁcant
decreases of the major BACE2 immunoreactive band in the
AD cases compared to controls (32%, P < 0.05). It should be
noted that although the major immunoreactive bands detected
by BACE1 and BACE2 antibodies in human brain prepara-tions are at a similar molecular weight, and both BACE1
and BACE2 levels are signiﬁcantly decreased in the AD cases,
there are diﬀerences in the BACE1 and BACE2 immunoreac-
tive proﬁle in individual cases (e.g. AD case 2 (A2) has high
level of BACE1 immunoreactivity, but very low levels of
BACE2). The decreased levels of BACE1 were rather speciﬁc
as levels of ﬂotillin-1 ( Fig. 3E), a marker for lipid rafts, which
can inﬂuence BACE1 levels [36] and b-secretase activity [37],
or b-actin were not signiﬁcantly diﬀerent when comparing con-
trol and AD cases ( Fig. 3F).
Regression analysis of b-secretase Vmax values and the lev-
els of BACE1, (73–75 kDa) for each AD (m) and control
(n) case given in Table 1 revealed no signiﬁcant correlation
between the levels of BACE1 and the Vmax when the entire
sample group was analysed (Fig. 4A) (r2 = 0.02; P = 0.66)
or between the individual AD (r2 = 0.06, P = 0.56) or control
(r2 = 0.02, P = 0.75) Vmax values and their BACE1 levels.
There was also no correlation detected between any of the
lower molecular weight BACE1 immunoreactive bands and
Vmax values (data not shown). We also evaluated the ratio
of b-secretase activity (both Vmax and Km values) to BACE1
(75 kDa, 70 kDa and 50 KDa) levels and BACE2 (75 kDa)
levels for each case, and did not ﬁnd this ratio to be signiﬁ-
cantly altered in AD cases compared to controls. However,
a signiﬁcantly higher Vmax for b-secretase (218%, P = 0.009)
was detected in cases with APOE genotype E4/E3 (n = 5)
against APOE E3/E3 (n = 9), (see Table 1, for APOE geno-
type).
Unlike the increased Vmax values for b-secretase activity,
regression analysis revealed that the decreased levels of both
BACE1 and BACE2 proteins correlated with disease severity
as measured by Braak staging for neuroﬁbrillary changes (0–
VI) (Fig. 4C and D) (r2 = 0.34, P < 0.02 for BACE1 73–
75 kDa, and r2 = 0.35, P = 0.02 BACE2). The decreased levels
of BACE1 and BACE2 also correlated signiﬁcantly with syn-
aptic loss as measured by levels of synaptophysin (Fig. 4B, E
and F) (r2 = 0.61, P < 0.0005; r2 = 0.72, P < 0.0001). There
was no correlation between BACE1 or BACE2 levels with
post-mortem delay, agonal status, age, gender, or brain weight.
Together, these results indicate that the decreases in both
BACE1 and BACE2 protein levels link to disease pathogene-
sis, and disease severity. However the increased Vmax in AD
cases or general Vmax values in all the cases, do not correlate
with either the levels of BACE1 the principal b-secretase in
brain, or show a direct relationship to the severity of disease
pathogenesis as measured by the degree of neuroﬁbrillary
changes or synaptophysin levels.4. Discussion
Deﬁning the mechanism of action of b-secretase is central to
understanding the development of Ab neuropathology in AD
[1,2]. The present study is the ﬁrst to describe the kinetics of
b-secretase activity in AD brain tissue, and shows that the
Vmax for this activity is signiﬁcantly increased in AD temporal
cortex, compared to non-disease control brain. This Vmax of b-
secretase did not correlate with Braak staging (I–VI) for neu-
roﬁbrillary changes [31] used to indicate the severity of AD.
Changes in b-secretase kinetics are found together with
changes in BACE1 and BACE2 protein levels. However, the
Vmax of b-secretase does not correlate with levels of BACE1,
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Fig. 4. (A) Regression analysis of BACE1 73–75 kDa versus b-secretase Vmax for control (j, n = 7) and AD (m, n = 8). No correlation was
detected between Vmax and BACE1 levels (Pearson correlation coeﬃcient r
2 = 0.02, P = 0.66). (B) Particulate fractions (20 lg protein per lane)
prepared from AD (n = 9, A1–A9) and control (n = 7, C1–C7) temporal cortex were analysed by Western blotting with anti-synaptophysin. Samples
were loaded in alternate lanes, as indicated on the top of immunoblot and Braak staging (0–VI) for neuroﬁbrillary changes is indicated.
Densitometric analysis revealed signiﬁcantly decreased (P < 0.05) synatophysin levels in AD cases compared to controls. Regression plots for BACE1
(C) and BACE2 (D) levels versus Braak staging (0–VI) for neuroﬁbrillary changes showing BACE1 and BACE2 levels correlate negatively with
Braak staging (r2 = 0.34, P < 0.02 for BACE1; r2 = 0.35, P = 0.02 for BACE2). Regression plots for BACE1, (E) and BACE2 (F) levels versus
synaptophysin levels. BACE1 75 kDa and BACE2 75 kDa levels correlate positively with synaptophysin levels (r2 = 0.61, P < 0.0005 for BACE1
75 kDa; r2 = 0.72, P < 0.0001 for BACE2 75 kDa).
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BACE2 levels show a signiﬁcant correlation with Braak stag-
ing (I–VI) for neuroﬁbrillary changes.
Analysis of b-secretase activity and kinetics in membrane-
enriched fractions from human brain, was performed utilising
a modiﬁcation of a previously described assay, which measures
ﬂuorescence emission after cleavage of a ﬂuorogenic APP pep-
tide substrate [34]. Speciﬁcity of the assay was ensured using a
b-secretase speciﬁc inhibitor P10–P4 0 StatVal (KTEET-SEVN(stat)VAEF), which completely abolished enzyme activ-
ity in a dose dependent manner, achieving an IC50 of
approximately 41 nM, similar to that previously described
with puriﬁed BACE1 (10 nM) and solubilised extracts from
human brain (30 nM) [5,18]. The present study revealed that
b-secretase activity in human temporal cortex followed
Michaelis–Menten kinetics, and demonstrated a hyperbolic
dependence of v (velocity) on substrate concentration, in both
control and AD cases. The mean Km values for enzyme activity
6558 J.H. Stockley et al. / FEBS Letters 580 (2006) 6550–6560detected in human brain are similar to values obtained using
puriﬁed full-length BACE1 [38], and these values were found
not to diﬀer signiﬁcantly in AD cases compared to controls.
Our results thus indicate that b-secretase activity, which has
previously been described to be increased in AD, using a single
concentration of substrate [17–20], is predominantly aﬀected at
the level of Vmax, showing that the speed at which b-secretase
cleaves substrate is signiﬁcantly enhanced in AD temporal cor-
tex. Our data draw attention to the usefulness of the present
assay in evaluating b-secretase kinetics in simply prepared frac-
tions from AD and control brain, in approaches to understand
enzyme mechanism, including the screening of potential b-
secretase inhibitors.
The ﬁnding that the Vmax for b-secretase activity is both var-
iable in normal human brain tissue and signiﬁcantly enhanced
in AD warranted our attention. As a ﬁrst step, we tested the
hypothesis that increases in Vmax, were due to increased
BACE1 protein levels. Previous studies indicate that BACE1
levels are increased in brain areas that are pathologically af-
fected in AD [17–19,25]. However, BACE1 levels have not
been associated consistently with increased b-secretase activity
in AD (for review see [39]). The speciﬁcity of the BACE1 anti-
body used in this study was analysed thoroughly. The antibody
used detected BACE1 clearly in human, rat and mouse brain
membrane enriched fractions, and in cells overexpressing
BACE1, but did not detect any immunoreactivity in brains
of BACE1 knock-out mice, or cross-react with BACE2. It is
of note that the clarity of the BACE1 immunoreactivity de-
tected by western immunoblotting was improved by analysing
membrane-enriched particulate fractions, rather than homoge-
nates which have been used in some previous studies compar-
ing BACE1 levels in AD and control brain [17,19,25].
In human mid-temporal cortex BACE1 was detected primar-
ily as a tightly spaced doublet of 73–75 kDa, and also as less
immunoreactive bands in the range 65–70 kDa and
45 kDa. The lower molecular weight BACE1 immunoreac-
tive bands, may represent less-glycosylated forms of BACE1
[22–24], splice variants [40] or degradation products of
BACE1. As it was not possible to conﬁrm the exact identity
of these less immunoreactive bands, we focused mainly on
the major BACE1 immunoreactive band (73–75 kDa) when
comparing levels in AD and control cases. Comparative anal-
ysis of the 73–75 kDa BACE1 levels in AD and control mid-
temporal cortex detected signiﬁcant decreases of BACE1 in
AD cases, which were particularly evident at late stages (V
and VI) of the disease, and whose loss correlated signiﬁcantly
with Braak staging for neuroﬁbrillary changes.
We also report decreased BACE2 protein levels in AD tem-
poral cortex which correlate with the degree of neuroﬁbrillary
pathology and synaptophysin loss. Although, BACE2 mRNA
is expressed at a much lower level than BACE1 in brain [4,13],
and BACE1 is the principal b-secretase in the brain, the rele-
vance of BACE2 protein levels to AD pathology requires fur-
ther investigation. In the present study, BACE2 was detected
at 73–75 kDa in human brain, 73 kDa in rat brain and
60 kDa in cells overexpressing BACE2. Previous studies have
detected BACE2 immunoreactivity at various molecular
weights in mammalian brain including: 80 kDa, 96 kDa and
200 kDa in Down’s syndrome and control foetal brain [27],
50 kDa in the frontal lobe of Down’s syndrome adult brain
[28]; 62 kDa in AD and control brain [4] and 72 and
65 kDa in rat brain [29]. These diﬀering molecular weightsmay be due to diﬀerent degrees of post-translational
modiﬁcation of BACE2 with development, and in diﬀering
brain areas.
We were surprised to detect decreased levels of BACE1 in
AD temporal cortex, as BACE1 levels have been found to be
unchanged [18], or increased (28%) in this region in AD [19],
and the general consensus from previous work is that BACE1
levels are increased in AD brain. However, previous western
immunoblot and ELISA measurements of BACE1 in AD have
used diﬀerent brain preparations to the present study, and
have not selected cases to examine the relationship between
BACE1 levels and the severity of AD, as measured by Braak
staging for neuroﬁbrillary changes [17–19,25]. This may ex-
plain the discrepancies between results. Our ﬁndings agree with
immunohistochemical studies which describe neuroﬁbrillary
tangles (NFT) to be associated with lower expression of
BACE1 in the transentorhinal cortex in AD [26]. In addition
synaptophysin levels, indicative of neuronal integrity and syn-
aptic loss, were signiﬁcantly decreased in AD cases, as previ-
ously reported in many studies [41,42], and correlated very
strongly with BACE1 levels. Thus both accumulation of neu-
roﬁbrillary pathology, and progressive synapse loss is closely
linked to loss of BACE1 in these cases. As the synapse repre-
sents an important site for Ab generation [43,44], the relation-
ship of BACE1 levels to synapse loss in AD may be important
in the altered control of the enzyme in AD.
There was no correlation between Vmax for b-secretase, and
BACE1 the principal b-secretase in brain, or a correlation be-
tween the Vmax and the degree of neuroﬁbrillary pathology,
or synaptophysin loss. This suggests that the velocity of b-
secretase may increase, and remain sustained irrespective of
the advancement of disease pathology (at least as measured
by Braak changes for neuroﬁbrillary changes), and in a fash-
ion not directly related to the absolute levels of BACE1, as
has been suggested previously [39]. Interestingly, we found
signiﬁcantly higher Vmax values in cases with APOE E3/E4
compared to APOE E3/E3, giving a very preliminary indica-
tion that the APOE E4 allele, which is a risk factor for AD
[29] is associated with increased Vmax for b-secretase. Many
factors besides actual BACE1 levels have been proposed to
regulate b-secretase activity, and may be important in further
understanding the functional relationship between BACE1,
and the increased Vmax for the enzyme detected in this study
in AD. These include: heparan sulphate proteoglycans [45,46],
cholesterol [47,48] lipid rafts [36,37,49], reticulon family mem-
bers [50,51] and PAR-4 [52]. Changed Vmax in the presence of
unchanged Km may reﬂect the loss of a non-competitive
inhibitor of b-secretase activity in AD brain, and increased
Vmax for b-secretase has been observed with BACE1 dimeri-
sation [53].
In light of our above ﬁndings, development of eﬀective treat-
ment to block b-secretase in AD should attempt to decrease
the velocity of the enzyme, and develop an understanding of
the mechanisms controlling the rate of b-secretase activity,
and the levels and localisation of BACE proteins, particularly
BACE1, in adult human brain and during the progression of
AD.Acknowledgements: Financial support was provided by the Health Re-
search Board of Ireland and the Government of Ireland Programme
for Research in Third Level Institutions. We thank Dr. Janet A. John-
ston (Queen’s University Belfast, UK) for very helpful advice and
J.H. Stockley et al. / FEBS Letters 580 (2006) 6550–6560 6559guidance on the b-secretase assay, and Dr. Justin V. McCarthy (Uni-
versity College Cork, Ireland) for providing us with constructs for
BACE1 and BACE2. We thank our colleagues in the Netherlands
Brain Bank, particularly Michiel Kooreman and Jose Wouda.References
[1] Vassar, R. (2002) Beta-secretase (BACE) as a drug target for
Alzheimer’s disease. Adv. Drug Deliv. Rev. 54, 1589–1602.
[2] Haass, C. (2004) Take ﬁve-BACE and the gamma-secretase
quartet conduct Alzheimer’s amyloid beta-peptide generation.
Embo J. 23, 483–488.
[3] Hussain, I., Powell, D., Howlett, D.R., Tew, D.G., Meek, T.D.,
Chapman, C., Gloger, I.S., Murphy, K.E., Southan, C.D., Ryan,
D.M., Smith, T.S., Simmons, D.L., Walsh, F.S., Dingwall, C. and
Christie, G. (1999) Identiﬁcation of a novel aspartic protease (Asp
2) as beta-secretase. Mol. Cell Neurosci. 14, 419–427.
[4] Hussain, I., Powell, D.J., Howlett, D.R., Chapman, G.A.,
Gilmour, L., Murdock, P.R., Tew, D.G., Meek, T.D., Chapman,
C., Schneider, K., Ratcliﬀe, S.J., Tattersall, D., Testa, T.T.,
Southan, C., Ryan, D.M., Simmons, D.L., Walsh, F.S., Dingwall,
C. and Christie, G. (2000) ASP1 (BACE2) cleaves the amyloid
precursor protein at the beta-secretase site. Mol. Cell. Neurosci.
16, 609–619.
[5] Sinha, S., Anderson, J.P., Barbour, R., Basi, G.S., Caccavello, R.,
Davis, D., Doan, M., Dovey, H.F., Frigon, N., Hong, J.,
Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J., Lieberburg,
I., Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D.,
Seubert, P., Suomensaari, S.M., Wang, S., Walker, D., Zhao, J.,
McConlogue, L. and John, V. (1999) Puriﬁcation and cloning of
amyloid precursor protein beta-secretase from human brain.
Nature 402, 537–540.
[6] Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz,
E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloﬀ, R.,
Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski,
M.A., Biere, A.L., Curran, E., Burgess, T., Louis, J.C., Collins,
F., Treanor, J., Rogers, G. and Citron, M. (1999) Beta-secretase
cleavage of Alzheimer’s amyloid precursor protein by the trans-
membrane aspartic protease BACE. Science 286, 735–741.
[7] Yan, R., Bienkowski, M.J., Shuck, M.E., Miao, H., Tory, M.C.,
Pauley, A.M., Brashier, J.R., Stratman, N.C., Mathews, W.R.,
Buhl, A.E., Carter, D.B., Tomasselli, A.G., Parodi, L.A.,
Heinrikson, R.L. and Gurney, M.E. (1999) Membrane-anchored
aspartyl protease with Alzheimer’s disease beta-secretase activity.
Nature 402, 533–537.
[8] Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A. and Tang, J.
(2000) Human aspartic protease memapsin 2 cleaves the beta-
secretase site of beta-amyloid precursor protein. Proc. Natl. Acad.
Sci. USA 97, 1456–1460.
[9] Farzan, M., Schnitzler, C.E., Vasilieva, N., Leung, D. and Choe,
H. (2000) BACE2, a beta -secretase homolog, cleaves at the beta
site and within the amyloid-beta region of the amyloid-beta
precursor protein. Proc. Natl. Acad. Sci. USA 97, 9712–9717.
[10] Luo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S.,
Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L.,
Louis, J.C., Yan, Q., Richards, W.G., Citron, M. and Vassar, R.
(2001) Mice deﬁcient in BACE1, the Alzheimer’s beta-secretase,
have normal phenotype and abolished beta-amyloid generation.
Nat. Neurosci. 4, 231–232.
[11] Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price,
D.L. and Wong, P.C. (2001) BACE1 is the major beta-secretase
for generation of Abeta peptides by neurons. Nat. Neurosci. 4,
233–234.
[12] Roberds, S.L., Anderson, J., Basi, G., Bienkowski, M.J., Bran-
stetter, D.G., Chen, K.S., Freedman, S.B., Frigon, N.L., Games,
D., Hu, K., Johnson-Wood, K., Kappenman, K.E., Kawabe,
T.T., Kola, I., Kuehn, R., Lee, M., Liu, W., Motter, R., Nichols,
N.F., Power, M., Robertson, D.W., Schenk, D., Schoor, M.,
Shopp, G.M., Shuck, M.E., Sinha, S., Svensson, K.A., Tatsuno,
G., Tintrup, H., Wijsman, J., Wright, S. and McConlogue, L.
(2001) BACE knockout mice are healthy despite lacking the
primary beta-secretase activity in brain: implications for Alzhei-
mer’s disease therapeutics. Hum. Mol. Genet. 10, 1317–1324.[13] Bennett, B.D., Babu-Khan, S., Loeloﬀ, R., Louis, J.C., Curran,
E., Citron, M. and Vassar, R. (2000) Expression analysis of
BACE2 in brain and peripheral tissues. J. Biol. Chem. 275, 20647–
20651.
[14] Yan, R., Munzner, J.B., Shuck, M.E. and Bienkowski, M.J.
(2001) BACE2 functions as an alternative alpha-secretase in cells.
J. Biol. Chem. 276, 34019–34027.
[15] Fluhrer, R., Capell, A., Westmeyer, G., Willem, M., Hartung, B.,
Condron, M.M., Teplow, D.B., Haass, C. and Walter, J. (2002) A
non-amyloidogenic function of BACE-2 in the secretory pathway.
J. Neurochem. 81, 1011–1020.
[16] Sun, X., He, G. and Song, W. (2006) BACE2, as a novel APP
theta-secretase, is not responsible for the pathogenesis of Alzhei-
mer’s disease in Down syndrome. Faseb J. 20, 1369–1376.
[17] Yang, L.B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang,
X.L., Beach, T., Sue, L., Wong, P., Price, D., Li, R. and Shen, Y.
(2003) Elevated beta-secretase expression and enzymatic activity
detected in sporadic Alzheimer disease. Nat. Med. 9, 3–4.
[18] Fukumoto, H., Cheung, B.S., Hyman, B.T. and Irizarry, M.C.
(2002) Beta-secretase protein and activity are increased in the
neocortex in Alzheimer disease. Arch. Neurol. 59, 1381–1389.
[19] Li, R., Lindholm, K., Yang, L.B., Yue, X., Citron, M., Yan, R.,
Beach, T., Sue, L., Sabbagh, M., Cai, H., Wong, P., Price, D. and
Shen, Y. (2004) Amyloid beta peptide load is correlated with
increased beta-secretase activity in sporadic Alzheimer’s disease
patients. Proc. Natl. Acad. Sci. USA 101, 3632–3637.
[20] Tyler, S.J., Dawbarn, D., Wilcock, G.K. and Allen, S.J. (2002)
alpha- and beta-secretase: profound changes in Alzheimer’s
disease. Biochem. Biophys. Res. Commun. 299, 373–376.
[21] Verheijen, J.H., Huisman, L.G., van Lent, N., Neumann, U.,
Paganetti, P., Hack, C.E., Bouwman, F., Lindeman, J., Bollen,
E.L. and Hanemaaijer, R. (2006) Detection of a soluble form of
BACE-1 in human cerebrospinal ﬂuid by a sensitive activity assay.
Clin. Chem. 52, 1168–1174.
[22] Huse, J.T., Pijak, D.S., Leslie, G.J., Lee, V.M. and Doms, R.W.
(2000) Maturation and endosomal targeting of beta-site amyloid
precursor protein-cleaving enzyme. The Alzheimer’s disease beta-
secretase. J. Biol. Chem. 275, 33729–33737.
[23] Capell, A., Steiner, H., Willem, M., Kaiser, H., Meyer, C.,
Walter, J., Lammich, S., Multhaup, G. and Haass, C. (2000)
Maturation and pro-peptide cleavage of beta-secretase. J. Biol.
Chem. 275, 30849–30854.
[24] Walter, J., Kaether, C., Steiner, H. and Haass, C. (2001) The cell
biology of Alzheimer’s disease: uncovering the secrets of secreta-
ses. Curr. Opin. Neurobiol. 11, 585–590.
[25] Holsinger, R.M., McLean, C.A., Beyreuther, K., Masters, C.L.
and Evin, G. (2002) Increased expression of the amyloid precursor
beta-secretase in Alzheimer’s disease. Ann. Neurol. 51, 783–786.
[26] Sun, A., Koelsch, G., Tang, J. and Bing, G. (2002) Localization of
beta-secretase memapsin 2 in the brain of Alzheimer’s patients
and normal aged controls. Exp. Neurol. 175, 10–22.
[27] Barbiero, L., Benussi, L., Ghidoni, R., Alberici, A., Russo, C.,
Schettini, G., Pagano, S.F., Parati, E.A., Mazzoli, F., Nicosia,
F., Signorini, S., Feudatari, E. and Binetti, G. (2003) BACE-2
is overexpressed in Down’s syndrome. Exp. Neurol. 182, 335–
345.
[28] Motonaga, K., Itoh, M., Becker, L.E., Goto, Y. and Takashima,
S. (2002) Elevated expression of beta-site amyloid precursor
protein cleaving enzyme 2 in brains of patients with Down
syndrome. Neurosci. Lett. 326, 64–66.
[29] Wen, Y., Onyewuchi, O., Yang, S., Liu, R. and Simpkins, J.W.
(2004) Increased beta-secretase activity and expression in rats
following transient cerebral ischemia. Brain Res. 1009, 1–8.
[30] Basi, G., Frigon, N., Barbour, R., Doan, T., Gordon, G.,
McConlogue, L., Sinha, S. and Zeller, M. (2003) Antagonistic
eﬀects of beta-site amyloid precursor protein-cleaving enzymes 1
and 2 on beta-amyloid peptide production in cells. J. Biol. Chem.
278, 31512–31520.
[31] Braak, H. and Braak, E. (1991) Neuropathological stageing of
Alzheimer-related changes. Acta Neuropathol. (Berl) 82, 239–259.
[32] Kelliher, M., Fastbom, J., Cowburn, R.F., Bonkale, W., Ohm,
T.G., Ravid, R., Sorrentino, V. and O’Neill, C. (1999) Alterations
in the ryanodine receptor calcium release channel correlate with
Alzheimer’s disease neuroﬁbrillary and beta-amyloid pathologies.
Neuroscience 92, 499–513.
6560 J.H. Stockley et al. / FEBS Letters 580 (2006) 6550–6560[33] Markwell, M.A., Haas, S.M., Bieber, L.L. and Tolbert, N.E.
(1978) A modiﬁcation of the Lowry procedure to simplify protein
determination in membrane and lipoprotein samples. Anal.
Biochem. 87, 206–210.
[34] Ermolieﬀ, J., Loy, J.A., Koelsch, G. and Tang, J. (2000)
Proteolytic activation of recombinant pro-memapsin 2 (Pro-
beta-secretase) studied with new ﬂuorogenic substrates. Biochem-
istry 39, 16263.
[35] Augustinack, J.C., Schneider, A., Mandelkow, E.M. and Hyman,
B.T. (2002) Speciﬁc tau phosphorylation sites correlate with
severity of neuronal cytopathology in Alzheimer’s disease. Acta
Neuropathol. (Berl) 103, 26–35.
[36] Cordy, J.M., Hussain, I., Dingwall, C., Hooper, N.M. and
Turner, A.J. (2003) Exclusively targeting beta-secretase to lipid
rafts by GPI-anchor addition up-regulates beta-site processing of
the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 100,
11735–11740.
[37] Hattori, C., Asai, M., Onishi, H., Sasagawa, N., Hashimoto, Y.,
Saido, T.C., Maruyama, K., Mizutani, S. and Ishiura, S. (2006)
BACE1 interacts with lipid raft proteins. J. Neurosci. Res. 84,
912–917.
[38] Gruninger-Leitch, F., Schlatter, D., Kung, E., Nelbock, P. and
Dobeli, H. (2002) Substrate and inhibitor proﬁle of BACE (beta-
secretase) and comparison with other mammalian aspartic pro-
teases. J. Biol. Chem. 277, 4687–4693.
[39] Johnston, J.A., Liu, W.W., Todd, S.A., Coulson, D.T., Murphy,
S., Irvine, G.B. and Passmore, A.P. (2005) Expression and activity
of beta-site amyloid precursor protein cleaving enzyme in
Alzheimer’s disease. Biochem. Soc. Trans. 33, 1096–1100.
[40] Zohar, O., Cavallaro, S., D’Agata, V. and Alkon, D.L. (2003)
Quantiﬁcation and distribution of beta-secretase alternative splice
variants in the rat and human brain. Brain Res. Mol. Brain Res.
115, 63–68.
[41] Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen,
L.A., McKeel Jr., D.W. and Morris, J.C. (2001) Altered expres-
sion of synaptic proteins occurs early during progression of
Alzheimer’s disease. Neurology 56, 127–129.
[42] Masliah, E., Terry, R.D., Alford, M., DeTeresa, R. and Hansen,
L.A. (1991) Cortical and subcortical patterns of synaptophysin-
like immunoreactivity in Alzheimer’s disease. Am. J. Pathol. 138,
235–246.[43] Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D.,
Iwatsubo, T., Sisodia, S. and Malinow, R. (2003) APP processing
and synaptic function. Neuron 37, 925–937.
[44] Cirrito, J.R., Yamada, K.A., Finn, M.B., Sloviter, R.S., Bales,
K.R., May, P.C., Schoepp, D.D., Paul, S.M., Mennerick, S. and
Holtzman, D.M. (2005) Synaptic activity regulates interstitial
ﬂuid amyloid-beta levels in vivo. Neuron 48, 913–922.
[45] Beckman, M., Holsinger, R.M. and Small, D.H. (2006) Heparin
activates beta-secretase (BACE1) of Alzheimer’s disease and
increases autocatalysis of the enzyme. Biochemistry 45, 6703–
6714.
[46] Scholeﬁeld, Z., Yates, E.A., Wayne, G., Amour, A., McDowell,
W. and Turnbull, J.E. (2003) Heparan sulfate regulates amyloid
precursor protein processing by BACE1, the Alzheimer’s beta-
secretase. J. Cell Biol. 163, 97–107.
[47] Kalvodova, L., Kahya, N., Schwille, P., Ehehalt, R., Verkade, P.,
Drechsel, D. and Simons, K. (2005) Lipids as modulators of
proteolytic activity of BACE: involvement of cholesterol, glyco-
sphingolipids, and anionic phospholipids in vitro. J. Biol. Chem.
280, 36815–36823.
[48] Ghribi, O., Larsen, B., Schrag, M. and Herman, M.M. (2006)
High cholesterol content in neurons increases BACE, beta-
amyloid, and phosphorylated tau levels in rabbit hippocampus.
Exp. Neurol. 200, 460–467.
[49] Tun, H., Marlow, L., Pinnix, I., Kinsey, R. and Sambamurti, K.
(2002) Lipid rafts play an important role in A beta biogenesis by
regulating the beta-secretase pathway. J. Mol. Neurosci. 19, 31–35.
[50] He, W., Lu, Y., Qahwash, I., Hu, X.Y., Chang, A. and Yan, R.
(2004) Reticulon family members modulate BACE1 activity and
amyloid-beta peptide generation. Nat. Med. 10, 959–965.
[51] Murayama, K.S., Kametani, F., Saito, S., Kume, H., Akiyama,
H. and Araki, W. (2006) Reticulons RTN3 and RTN4-B/C
interact with BACE1 and inhibit its ability to produce amyloid
beta-protein. Eur. J. Neurosci. 24, 1237–1244.
[52] Xie, J. and Guo, Q. (2005) PAR-4 is involved in regulation of beta
-secretase cleavage of the Alzheimer’s amyloid precursor protein.
J. Biol. Chem. 280, 13824–13832.
[53] Westmeyer, G.G., Willem, M., Lichtenthaler, S.F., Lurman, G.,
Multhaup, G., Assfalg-Machleidt, I., Reiss, K., Saftig, P. and
Haass, C. (2004) Dimerization of beta-site beta-amyloid precursor
protein-cleaving enzyme. J. Biol. Chem. 279, 53205–53212.
